Back to Results

Acumen Pharmaceuticals Inc (ABOS)

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted treatments for Alzheimer’s disease. Its lead candidate is Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 designed to target soluble amyloid-beta oligomers. The program has completed a phase 1 study, INTERCEPT-AD, and is being evaluated in the phase 2 ALTITUDE-AD trial. Acumen also has a collaboration and license agreement with Halozyme, Inc. related to a subcutaneous formulation of Sabirnetug. Founded in 1996, the company is headquartered in Newton, Massachusetts, and its common stock trades on the NASDAQ under the ticker ABOS.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date Price-to-Book Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-ABOS
$0.31
45.3% Upside
Undervalued
$1
367.3% Upside
Bargain
Weak
0.0%
March 29, 2027
0.4x
15.464 M
-36.815 M
63.0%
51.2%
-21.2
84.6%
Valuation • Fair Value

Acumen Pharmaceuticals Inc (NASDAQ-ABOS) Fair Value by Valuation Model

Review the available estimates for Acumen Pharmaceuticals Inc (NASDAQ-ABOS), including DCF Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$0.31

Estimated upside of 45.3% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

DCF Fair Value

$0.31

Discounted cash flow valuation reference.

Comps Fair Value

$0.31

Comparable-company valuation reference.

Analyst Price Target

$1

Analysts imply upside of 367.3%.

How to read these valuation models

Use the 5 available valuation references for Acumen Pharmaceuticals Inc (NASDAQ-ABOS) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Acumen Pharmaceuticals Inc (NASDAQ-ABOS)

Review the profitability and growth indicators currently supported by the latest data.

Revenue Forecast

0 K

Forward revenue estimate.

EBITDA

-104.7 M

Current operating profitability reference.

EBITDA Forecast

-113.6 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Acumen Pharmaceuticals Inc (NASDAQ-ABOS) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Acumen Pharmaceuticals Inc (NASDAQ-ABOS)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Weak

Financial pressure deserves closer review.

Piotroski Score

1

Weak quality score that deserves closer review.

Altman Z-Score

-21.2

Lower score that deserves closer risk review.

FCF / Net Income

84.6%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Acumen Pharmaceuticals Inc (NASDAQ-ABOS). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Acumen Pharmaceuticals Inc (NASDAQ-ABOS)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

March 29, 2027

Days to Earnings

143

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Acumen Pharmaceuticals Inc (NASDAQ-ABOS), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Acumen Pharmaceuticals Inc (NASDAQ-ABOS) Stock Forecast & Technical Outlook

Review Acumen Pharmaceuticals Inc (NASDAQ-ABOS) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Buy

The 15-minute technical read for Acumen Pharmaceuticals Inc (NASDAQ-ABOS) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Acumen Pharmaceuticals Inc (NASDAQ-ABOS) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Acumen Pharmaceuticals Inc (NASDAQ-ABOS) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Acumen Pharmaceuticals Inc (NASDAQ-ABOS) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Acumen Pharmaceuticals Inc (NASDAQ-ABOS) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Acumen Pharmaceuticals Inc (NASDAQ-ABOS)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Hold

Based on the available recommendation mix, Acumen Pharmaceuticals Inc (NASDAQ-ABOS) has a Hold consensus, with 1 buy, 3 hold and 1 sell recommendations in the current data set.

Buy 1
Hold 3
Sell 1
FAQ • Fast Investor Answers

Acumen Pharmaceuticals Inc (NASDAQ-ABOS) Stock FAQ

Data-supported answers about Acumen Pharmaceuticals Inc (NASDAQ-ABOS), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$0.31
Estimated upside 45.3%
Valuation Rating
Undervalued
Estimated upside of 45.3%
Analyst Target
$1
Implied upside 367.3%
Financial Health
Weak
Current financial-health read

The current fair value estimate for Acumen Pharmaceuticals Inc (NASDAQ-ABOS) is $0.31. This implies an estimated upside of 45.3% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 45.3% versus the current market price.

The available analyst price target for Acumen Pharmaceuticals Inc (NASDAQ-ABOS) is $1. The analyst target implies estimated upside of 367.3%.

The current financial health read for Acumen Pharmaceuticals Inc (NASDAQ-ABOS) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Acumen Pharmaceuticals Inc (NASDAQ-ABOS) is March 29, 2027.

The latest available data indicates no current dividend yield for Acumen Pharmaceuticals Inc (NASDAQ-ABOS).

The current market capitalization listed for Acumen Pharmaceuticals Inc is 15.464 M.

The current enterprise value listed for Acumen Pharmaceuticals Inc is -36.815 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Acumen Pharmaceuticals Inc is NASDAQ-ABOS, and the stock is listed on NASDAQ.

Acumen Pharmaceuticals Inc (NASDAQ-ABOS) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Acumen Pharmaceuticals Inc is 63.0%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Acumen Pharmaceuticals Inc is 51.2%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

ABBV NYSE AbbVie Inc Fair Value Fair Market Cap 509.5 B
AMGN NASDAQ Amgen Inc Fair Value Fair Market Cap 249 B
GILD NASDAQ Gilead Sciences Inc Fair Value Overvalued Market Cap 207.9 B
VRTX NASDAQ Vertex Pharmaceuticals Inc Fair Value Fair Market Cap 137.5 B
MRNA NASDAQ Moderna Inc Fair Value Overvalued Market Cap 96.399 B
REGN NASDAQ Regeneron Pharmaceuticals Inc Fair Value Undervalued Market Cap 90.518 B
ARGX NASDAQ argenx NV ADR Fair Value Fair Market Cap 57.239 B
NTRA NASDAQ Natera Inc Fair Value Overvalued Market Cap 52.434 B
ONC NASDAQ BeOne Medicines AG DRC Fair Value Fair Market Cap 44.031 B
RVMD NASDAQ Revolution Medicines Inc Fair Value Fair Market Cap 38.077 B
BIIB NASDAQ Biogen Inc Fair Value Fair Market Cap 36.058 B
GMAB NASDAQ Genmab AS Fair Value Fair Market Cap 32.603 B
ROIV NASDAQ Roivant Sciences Ltd Fair Value Overvalued Market Cap 26.451 B
UTHR NASDAQ United Therapeutics Corporation Fair Value Fair Market Cap 24.093 B
INCY NASDAQ Incyte Corporation Fair Value Undervalued Market Cap 24.048 B
INSM NASDAQ Insmed Inc Fair Value Fair Market Cap 23.855 B
BNTX NASDAQ BioNTech SE Fair Value Fair Market Cap 21.287 B
ALNY NASDAQ Alnylam Pharmaceuticals Inc Fair Value Undervalued Market Cap 20.983 B
EXEL NASDAQ Exelixis Inc Fair Value Fair Market Cap 16.751 B
ASND NASDAQ Ascendis Pharma AS Fair Value Fair Market Cap 16.65 B